Top Gainer for 2-16-23: $AMAM

jktrades (45)in #topgainers • 2 years ago

$AMAM - ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer: https://finance.yahoo.com/news/arx517-ambrx-proprietary-anti-psma-130000665.html

2 years ago in #topgainers by jktrades (45)

$0.00